BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 38366101)

  • 1. CXCR4 overexpression in chronic lymphocytic leukemia associates with poorer prognosis: A prospective, single-center, observational study.
    Xue X; Wen Z; Zhang X; Yang Y; Li Y; Liao R; Zheng Q; Fu Y; Liu Y; Liao H
    Genes Immun; 2024 Apr; 25(2):117-123. PubMed ID: 38366101
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CXCR4 and SDF-1 expression in B-cell chronic lymphocytic leukemia and stage of the disease.
    Barretina J; Juncà J; Llano A; Gutiérrez A; Flores A; Blanco J; Clotet B; Esté JA
    Ann Hematol; 2003 Aug; 82(8):500-505. PubMed ID: 12783211
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Expression of the chemokine receptors CXCR4 and CCR7 and disease progression in B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma.
    Ghobrial IM; Bone ND; Stenson MJ; Novak A; Hedin KE; Kay NE; Ansell SM
    Mayo Clin Proc; 2004 Mar; 79(3):318-25. PubMed ID: 15008605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protein kinase D-dependent CXCR4 down-regulation upon BCR triggering is linked to lymphadenopathy in chronic lymphocytic leukaemia.
    Saint-Georges S; Quettier M; Bouyaba M; Le Coquil S; Laurienté V; Guittat L; Lévy V; Ajchenbaum-Cymbalista F; Varin-Blank N; Le Roy C; Ledoux D
    Oncotarget; 2016 Jul; 7(27):41031-41046. PubMed ID: 27127886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of the chemokine receptor CXCR4 in B cell chronic lymphocytic leukemia is associated with increased functional response to stromal cell-derived factor-1 (SDF-1).
    Möhle R; Failenschmid C; Bautz F; Kanz L
    Leukemia; 1999 Dec; 13(12):1954-9. PubMed ID: 10602415
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the CXCR4 pathway using a novel anti-CXCR4 IgG1 antibody (PF-06747143) in chronic lymphocytic leukemia.
    Kashyap MK; Amaya-Chanaga CI; Kumar D; Simmons B; Huser N; Gu Y; Hallin M; Lindquist K; Yafawi R; Choi MY; Amine AA; Rassenti LZ; Zhang C; Liu SH; Smeal T; Fantin VR; Kipps TJ; Pernasetti F; Castro JE
    J Hematol Oncol; 2017 May; 10(1):112. PubMed ID: 28526063
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Elucidating the CXCL12/CXCR4 signaling network in chronic lymphocytic leukemia through phosphoproteomics analysis.
    O'Hayre M; Salanga CL; Kipps TJ; Messmer D; Dorrestein PC; Handel TM
    PLoS One; 2010 Jul; 5(7):e11716. PubMed ID: 20661426
    [TBL] [Abstract][Full Text] [Related]  

  • 8. CXCL12-induced VLA-4 activation is impaired in trisomy 12 chronic lymphocytic leukemia cells: a role for CCL21.
    Ganghammer S; Hutterer E; Hinterseer E; Brachtl G; Asslaber D; Krenn PW; Girbl T; Berghammer P; Geisberger R; Egle A; Zucchetto A; Kruschinski A; Gattei V; Chigaev A; Greil R; Hartmann TN
    Oncotarget; 2015 May; 6(14):12048-60. PubMed ID: 25895128
    [TBL] [Abstract][Full Text] [Related]  

  • 9. PIM kinases are essential for chronic lymphocytic leukemia cell survival (PIM2/3) and CXCR4-mediated microenvironmental interactions (PIM1).
    Decker S; Finter J; Forde AJ; Kissel S; Schwaller J; Mack TS; Kuhn A; Gray N; Follo M; Jumaa H; Burger M; Zirlik K; Pfeifer D; Miduturu CV; Eibel H; Veelken H; Dierks C
    Mol Cancer Ther; 2014 May; 13(5):1231-45. PubMed ID: 24659821
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Chronic lymphocytic leukemia B cells express functional CXCR4 chemokine receptors that mediate spontaneous migration beneath bone marrow stromal cells.
    Burger JA; Burger M; Kipps TJ
    Blood; 1999 Dec; 94(11):3658-67. PubMed ID: 10572077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MicroRNA-155 influences B-cell receptor signaling and associates with aggressive disease in chronic lymphocytic leukemia.
    Cui B; Chen L; Zhang S; Mraz M; Fecteau JF; Yu J; Ghia EM; Zhang L; Bao L; Rassenti LZ; Messer K; Calin GA; Croce CM; Kipps TJ
    Blood; 2014 Jul; 124(4):546-54. PubMed ID: 24914134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CXCR4 and CD74 together enhance cell survival in response to macrophage migration-inhibitory factor in chronic lymphocytic leukemia.
    Thavayogarajah T; Sinitski D; El Bounkari O; Torres-Garcia L; Lewinsky H; Harjung A; Chen HR; Panse J; Vankann L; Shachar I; Bernhagen J; Koschmieder S
    Exp Hematol; 2022 Nov; 115():30-43. PubMed ID: 36096455
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Down-regulation of CXCR4 and CD62L in chronic lymphocytic leukemia cells is triggered by B-cell receptor ligation and associated with progressive disease.
    Vlad A; Deglesne PA; Letestu R; Saint-Georges S; Chevallier N; Baran-Marszak F; Varin-Blank N; Ajchenbaum-Cymbalista F; Ledoux D
    Cancer Res; 2009 Aug; 69(16):6387-95. PubMed ID: 19654311
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CXCR4 as a prognostic marker in Egyptian chronic lymphocytic leukemia patients.
    El-Sherif WT; Salah El-Din EM; Aly MM; Said MG; Nigm DA
    Egypt J Immunol; 2021 Jul; 28(3):114-126. PubMed ID: 34185460
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD49d is an independent prognostic marker that is associated with CXCR4 expression in CLL.
    Majid A; Lin TT; Best G; Fishlock K; Hewamana S; Pratt G; Yallop D; Buggins AG; Wagner S; Kennedy BJ; Miall F; Hills R; Devereux S; Oscier DG; Dyer MJ; Fegan C; Pepper C
    Leuk Res; 2011 Jun; 35(6):750-6. PubMed ID: 21093051
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Genetic variation in CXCR4 and risk of chronic lymphocytic leukemia.
    Crowther-Swanepoel D; Qureshi M; Dyer MJ; Matutes E; Dearden C; Catovsky D; Houlston RS
    Blood; 2009 Nov; 114(23):4843-6. PubMed ID: 19812382
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Small peptide inhibitors of the CXCR4 chemokine receptor (CD184) antagonize the activation, migration, and antiapoptotic responses of CXCL12 in chronic lymphocytic leukemia B cells.
    Burger M; Hartmann T; Krome M; Rawluk J; Tamamura H; Fujii N; Kipps TJ; Burger JA
    Blood; 2005 Sep; 106(5):1824-30. PubMed ID: 15905192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ulocuplumab (BMS-936564 / MDX1338): a fully human anti-CXCR4 antibody induces cell death in chronic lymphocytic leukemia mediated through a reactive oxygen species-dependent pathway.
    Kashyap MK; Kumar D; Jones H; Amaya-Chanaga CI; Choi MY; Melo-Cardenas J; Ale-Ali A; Kuhne MR; Sabbatini P; Cohen LJ; Shelat SG; Rassenti LZ; Kipps TJ; Cardarelli PM; Castro JE
    Oncotarget; 2016 Jan; 7(3):2809-22. PubMed ID: 26646452
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differences between chronic lymphocytic leukaemia and small lymphocytic lymphoma cells by proteomic profiling and SNP microarray analysis.
    Tooze JA; Hamzic E; Willis F; Pettengell R
    Cancer Genet; 2017 Dec; 218-219():20-38. PubMed ID: 29153094
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined CXCR3/CXCR4 measurements are of high prognostic value in chronic lymphocytic leukemia due to negative co-operativity of the receptors.
    Ganghammer S; Gutjahr J; Hutterer E; Krenn PW; Pucher S; Zelle-Rieser C; Jöhrer K; Wijtmans M; Leurs R; Smit MJ; Gattei V; Greil R; Hartmann TN
    Haematologica; 2016 Mar; 101(3):e99-102. PubMed ID: 26589908
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.